[go: up one dir, main page]

PE20080070A1 - Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c - Google Patents

Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c

Info

Publication number
PE20080070A1
PE20080070A1 PE2007000585A PE2007000585A PE20080070A1 PE 20080070 A1 PE20080070 A1 PE 20080070A1 PE 2007000585 A PE2007000585 A PE 2007000585A PE 2007000585 A PE2007000585 A PE 2007000585A PE 20080070 A1 PE20080070 A1 PE 20080070A1
Authority
PE
Peru
Prior art keywords
alkyl
hepatitis
cyclopropyl
virus
inhibitors
Prior art date
Application number
PE2007000585A
Other languages
English (en)
Inventor
John A Bender
Min Ding
Robert G Gentles
Piyasena Hewawasam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20080070A1 publication Critical patent/PE20080070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A COMPUESTOS DE DERIVADOS DE INDOLOBENZAZEPINA FUSIONADOS A CICLOPROPILO DE FORMULA (I) DONDE R1 ES CO2R5 O CONR6R7, DONDE R5 ES H O ALQUILO(C1-C6); R6 ES H, ALQUILO(C1-C6), ALQUIL(C1-C6)SO2, CICLOALQUIL(C3-C7)SO2, ENTRE OTROS; R7 ES H O ALQUILO(C1-C6); R2 ES UN COMPUESTO DE FORMULA (i) O (ii), DONDE R8 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), AMINOCARBONILO, ENTRE OTROS; R3 ES H, HALO, ALQUILO(C1-C6), OH, ENTRE OTROS; R4 ES CICLOALQUILO(C3-C7). SON COMPUESTOS PREFERIDOS: (+/-)-8-CICLOHEXIL-N-(METILSULFONIL)-1,1a,2,12b-TETRAHIDRO-11-METOXI-1a-(3-METIL-3,8-DIAZABICICLO[3.2.1]OCTANO-8-CARBONIL)CICLOPROP[d]INDOLO[2,1-a][2]BENZAZEPINA-5-CARBOXAMIDA, (+/-)-8-CICLOHEXIL-N-(ETILSULFONIL)-1,1a,2,12b-TETRAHIDRO-11-METOXI-1a-(3-METIL-3,8-DIAZABICICLO[3.2.1]OCTANO-8-CARBONIL)CICLOPROP[d]INDOLO[2,1-a][2]BENZAZEPINA-5-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA POLIMERASA NS5B DEL VIRUS DE LA HEPATITIS C SIENDO UTILES EN EL TRATAMIENTO DE LA INFECCION DE LA HEPATITIS C
PE2007000585A 2006-05-17 2007-05-15 Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c PE20080070A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80112506P 2006-05-17 2006-05-17
US80200506P 2006-05-19 2006-05-19
US85208406P 2006-10-16 2006-10-16
US89475707P 2007-03-14 2007-03-14

Publications (1)

Publication Number Publication Date
PE20080070A1 true PE20080070A1 (es) 2008-03-10

Family

ID=38512732

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000585A PE20080070A1 (es) 2006-05-17 2007-05-15 Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c

Country Status (24)

Country Link
US (1) US7456166B2 (es)
EP (1) EP2024375B1 (es)
JP (1) JP5284952B2 (es)
KR (1) KR101417145B1 (es)
AR (1) AR061008A1 (es)
AT (1) ATE501156T1 (es)
AU (1) AU2007253998B2 (es)
BR (1) BRPI0711821A2 (es)
CA (1) CA2651690C (es)
CY (1) CY1111526T1 (es)
DE (1) DE602007013036D1 (es)
DK (1) DK2024375T3 (es)
EA (1) EA015286B1 (es)
HR (1) HRP20110194T1 (es)
IL (1) IL195025A (es)
MX (1) MX2008014435A (es)
NO (1) NO341663B1 (es)
NZ (1) NZ572555A (es)
PE (1) PE20080070A1 (es)
PL (1) PL2024375T3 (es)
SI (1) SI2024375T1 (es)
TW (1) TWI401244B (es)
WO (1) WO2007136982A1 (es)
ZA (1) ZA200809548B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ATE469155T1 (de) * 2006-05-25 2010-06-15 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
JP5211078B2 (ja) 2007-03-13 2013-06-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2142215B1 (en) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of hcv infection
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ATE533771T1 (de) * 2007-11-20 2011-12-15 Bristol Myers Squibb Co Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
NZ585370A (en) 2007-12-19 2012-09-28 Boehringer Ingelheim Int Viral polymerase inhibitors
DK2238142T3 (da) 2007-12-24 2012-10-08 Janssen R & D Ireland Makrocykliske indoler som hepatitis C-virusinhibitorer
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5870098B2 (ja) 2010-06-24 2016-02-24 ヤンセン・サイエンシズ・アイルランド・ユーシー １３−シクロヘキシル−３−メトキシ−６−［メチル−（２−｛２−［メチル−（スルファモイル）−アミノ］−エトキシ｝−エチル）−カルバモイル］−７Ｈ−インドロ−［２，１−ａ］−［２］−ベンズアゼピン−１０−カルボン酸の製造
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
EA025391B1 (ru) 2012-07-18 2016-12-30 Бристол-Майерс Сквибб Холдингс Айеленд НОВЫЕ СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ (4bS,5aR)-12-ЦИКЛОГЕКСИЛ-N-(N,N-ДИМЕТИЛСУЛЬФАМОИЛ)-3-МЕТОКСИ-5a-((1R,5S)-3-МЕТИЛ-3,8-ДИАЗАБИЦИКЛО[3.2.1]ОКТАН-8-КАРБОНИЛ)-4b,5,5a,6-ТЕТРАГИДРОБЕНЗО[3,4]ЦИКЛОПРОПА[5,6]АЗЕПИНО[1,2-a]ИНДОЛ-9-КАРБОКСАМИДА
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US752354A (en) * 1904-02-16 Composition post
US753137A (en) * 1904-02-23 Dust-pan
US756203A (en) * 1903-11-14 1904-04-05 Oliver E Barthel Muffler.
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006040039A1 (de) 2004-10-13 2006-04-20 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
WO2006046030A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents

Also Published As

Publication number Publication date
TWI401244B (zh) 2013-07-11
BRPI0711821A2 (pt) 2012-01-17
EA015286B1 (ru) 2011-06-30
PL2024375T3 (pl) 2011-07-29
NO341663B1 (no) 2017-12-18
AR061008A1 (es) 2008-07-30
DE602007013036D1 (de) 2011-04-21
EP2024375B1 (en) 2011-03-09
KR20090008344A (ko) 2009-01-21
MX2008014435A (es) 2008-11-27
US20070270405A1 (en) 2007-11-22
NO20084637L (no) 2008-12-15
CA2651690A1 (en) 2007-11-29
JP2009537557A (ja) 2009-10-29
ZA200809548B (en) 2009-12-30
AU2007253998B2 (en) 2012-03-15
CA2651690C (en) 2014-11-04
HK1122814A1 (en) 2009-05-29
AU2007253998A1 (en) 2007-11-29
NZ572555A (en) 2010-11-26
IL195025A0 (en) 2009-08-03
EA200802346A1 (ru) 2009-06-30
EP2024375A1 (en) 2009-02-18
HRP20110194T1 (hr) 2011-04-30
KR101417145B1 (ko) 2014-07-08
IL195025A (en) 2013-09-30
DK2024375T3 (da) 2011-06-27
CY1111526T1 (el) 2016-02-10
TW200804282A (en) 2008-01-16
SI2024375T1 (sl) 2011-10-28
JP5284952B2 (ja) 2013-09-11
US7456166B2 (en) 2008-11-25
WO2007136982A1 (en) 2007-11-29
ATE501156T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20080704A1 (es) Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo
BR112013007696A2 (pt) composto, composição farmacêutica, usos do referido composto e da referida composição
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EA200900298A1 (ru) Ингибиторы вируса гепатита с
PE20070676A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
NO20090453L (no) Hepatitt C Virusinhibitorer
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
PE20091103A1 (es) Inhibidores de la polimerasa virica
EA201100390A1 (ru) Соединения для лечения гепатита с
DK2250163T3 (da) Hepatitis C-virusinhibitorer
NZ595186A (en) Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection
WO2012166716A3 (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
PE20070983A1 (es) COMPUESTOS DERIVADOS DE 3-DESAZAPURINA COMO AGONISTAS DEL RECEPTOR Toll-LIKE (TLR7)
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
UA116616C2 (uk) Інгібітори hcv серинової протеази, отримані з макроциклічного проліну
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
WO2010084115A3 (en) Antiviral agents
PE20130183A1 (es) Fosforamidatos de nucleosido

Legal Events

Date Code Title Description
FG Grant, registration